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Background: In order to allocate health care resources more efficiently it is necessary to 
relate health improvements provided by new medicines with their cost. It is necessary to 
ascertain when the additional cost of introducing a new health technology is justified by 
the additional health gain produced. Eplerenone is a new medicine that reduces the risk 
of death after myocardial infarction (MI) but produces additional cost to the health 
system. The contingent valuation approach can be used to measure the monetary value of 
this risk reduction. Objective: to estimate society’s willingness to pay (WTP) for a new 
medicine that reduces by 2% the risk of death after MI. Methods: We used a contingent 
valuation approach to evaluate WTP amongst members of the general population. We 
used the ex-ante and the ex-post approach. In the ex-ante approach subjects are asked if 
they would accept an increase in their taxes in order to have access to Eplerenone should 
they need it in the future. In the ex-post approach subjects are asked if they would pay a 
certain amount of money as co-payment per month during five years if they suffered a 
MI. We used the Dichotomous Choice method, using five bids in each approach. The 
WTP was estimated using both single-bound and double-bound dichotomous choice 
(SBDC, DBDC). Extensive piloting (n=187) preceded the final survey (n=350). Results: 
The WTP in the ex-ante case was €58 per year under both SBDC and DBDC. In the ex-
post case monthly WTP was €144 for the SBDC and €85 for the DBDC. Subjects with 
higher income and subjects with a higher perception of risk showed a higher WTP 
(p<0.05). Conclusions: Society is willing to pay an additional amount of money in order 
to give Eplerenone to present and future patients. We estimate that €85 per month is a 
conservative estimate of the monetary value of a 2% risk reduction in mortality after MI 
and to spend this additional amount of money in Eplerenone can be considered an 
efficient policy. 
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One of the most important questions for managers of health care systems is how to 
allocate scarce resources. This question is especially important in the case of new 
medical technologies (medicines, medical devices) that are more effective than the 
standard but more costly. A large part of the increase in health expenditures is due to 
these new technologies
1. To have more effective medical technologies is something 
desirable from any perspective; however, this technological progress is putting health 
systems under financial stress
2. Given budgetary restrictions health care managers have 
to choose those technologies that give greater value for money.  
 
Faced with these resource allocation problems economists have elaborated a 
methodology generally known as Economic Evaluation. Efficiency requires that benefits 
are maximised and opportunity costs minimised. In order to allocate resources in an 
efficient way we need good measures of the costs and benefits of medical technologies. 
If a new procedure is less costly and at least as effective as the status quo, it would be 
judged to be better (more technically efficient). If a new procedure is more costly and 
more effective, a judgment has to be made about whether the extra cost is worth the 
gains achieved (a question of allocative efficiency since more resources would have to be 
allocated to this technology). Traditionally, this Economic Evaluation has moved 
between Cost-Effectiveness Analysis (CEA) and Cost-Benefit Analysis (CBA). CEA can 
deal with questions of technical efficiency but not of allocative efficiency. CBA can deal 
with both kinds of problems
3. 
 
In spite of being a more powerful tool, CBA has been less used in the evaluation of 
medical technologies since it requires the valuation of health in monetary units.   
However, when we have to take decisions about medical technologies that request more 
funds we face a decision that involves allocative efficiency and CBA is the appropriate 
tool
3. In this paper we want to respond to a question of allocative efficiency. We want to 
know how much a National Health Service (NHS) like the Spanish one should invest in 
order to fund a new medicine that is more effective than the status quo but also more 
costly. Eplerenone
4 is a selective aldosterone blocker that reduces morbidity and 
mortality among patients with acute myocardial infarction (MI) complicated by left 
ventricular dysfunction and heart failure. It is therefore a medicine that increases the 
effectiveness of the treatment of MI. However, it requires an additional investment from 
the health service. The question is, then, up to what point is it sensible to invest more 
resources in order to increase the effectiveness of a treatment for MI? All health systems 
have to establish limits on what it is reasonable to spend in a medical treatment even if 
health effects are very important (reduction in mortality), like in this case. 
 
Since Eplerenone reduces mortality we need to estimate the monetary value that people 
attach to a reduction in the risk of death. In order to do so we use a technique known as 
Contingent Valuation (CV)
5. This method has been mainly developed to value changes 
in goods that cannot be traded on a market like cleaner air, noise reduction or preserving 
a recreational area. The CV has also been applied to assess changes in health
6. In this 
paper, we will use the CV method in order to elicit the monetary value of Eplerenone. 














The study population comprised 537 members of the Spanish general population. Initial 
telephone calls were made to a random sample of households based on random digit 
dialing. The persons were asked to participate in a survey.  Those who accepted to 
participate were interviewed face-to-face at the subject’s home in the second half of 
2004. The strata followed the age and gender structure of the population. There is some 
debate in the literature about which is the correct population that has to provide their 
preferences in order to take resource allocation decisions in health care
7. Most studies 
have been conducted asking patients about their WTP. However, there are theoretical 
arguments in favor of using members of the general population
8 as the relevant 
population. One reason is that when deciding whether a new treatment will be funded or 
not we should include the preferences of all subjects that can benefit from this program 
in the future. It has been argued that for CBA “the relevant population is a sample of all 
persons who may benefit (or lose) by the introduction of the program within a defined 
jurisdiction.”
9 In our case, the relevant population would then be the general population 
since all of them are susceptible of using Eplerenone in the future.  
 
The main argument most frequently quoted in favor of using patients as subjects is that 
they are in a better position to value a medicine that improves their health. This argument 
is less valid in our case since we are dealing with mortality risks and this is a kind of 
outcome that can be easily understood by members of the general population. The use of 
patients as subjects in a WTP study also has very important problems related with 
fairness. In many instances patients have a lower income than the general population, 
and it is the average income of a country that has to establish the budgetary restrictions 
for the NHS, and not the average income of patients. In our case, this is quite clear. As 
the average age of patients is 67, most of the users of Eplerenone are retired people that 
have (presumably) a lower income than those who are in the active population. In 
general, since WTP is constrained by income and since it is the average income of the 
general population that has to determine the limit that a society can spend on health, we 
think that members of the general population are the right sample to be consulted in 
WTP studies, at least if the objective of the study is to decide whether a technology has 





It has been suggested
8 above that if we use the general population in a CV study, WTP 
questions have to be asked in an insurance context, that is, how much they would be 
willing to pay in order to have access to a medical technology in case they need it. This 
is also known as an ex-ante perspective. Although we believe this is a correct theoretical 








probability of needing the medicine in the future and the probability of having a better 
health outcome if the medicine is needed. Since the Spanish health system is basically 
funded out of taxes, the WTP ex-ante question has to be asked in terms of an increase in 
taxes
10. Given that the cognitive burden is quite heavy under this kind of framework, we 
also framed the question under conditions of certainty, that is, we asked about their WTP 
in case they were patients. This is the ex-post perspective. It has been argued that this 
framework provides a conservative estimate on WTP for health gains
11.  
 
Willingness to pay 
 
There are several formats that can be used to ask WTP questions. Among those are 
“open-ended”, “bidding game”, “payment card” and dichotomous choice
12. In the open-
ended (OE) question the respondent is asked for her maximum WTP for something that 
she values. The bidding game offers a sequence of bids (the certain amounts that people 
are asked to pay) to the respondent so that her maximum WTP can be elicited. Payment 
card is another mode of question used in CV. The respondent is faced with a payment 
card containing a range of payment amounts, and is asked to mark the highest amount 
she would be willing to pay to get the program or policy in question. Dichotomous 
choice (DC) or binary question is characterized by a bid offered to the respondent that 
she can accept or reject.  
 
The NOAA panel on Contigent Valuation
13 recommends the use of the DC format since 
it is cognitively less demanding, people are used to take dichotomous decisions in 
markets (to buy a product or not, given a price) and also has good incentive-compatible 
properties
14. Incentive compatibility means that the subject does not have, in principle, 
any incentive to respond in a strategic way. It is in her best interest to reveal preferences 
honestly. This is not the case of other response modes. For example, in the bidding game 
format, subjects may anchor their response in the first amount they are offered (the so-
called starting-point bias). Within the DC format, there are basically two options, 
namely, single bound and double bound formats. In single bound dichotomous choice 
(SBDC) only one YES/NO question is asked to the subject and in double bound 
dichotomous choice (DBDC) the respondent is asked a second YES/NO question 
depending on her previous answer. DBDC does not have the same good incentive 
compatible properties as the SBDC. For example, if a subject says yes to the first 
question and is asked a second question with a higher bid, she can receive this second bid 
as an unpleasant surprise and she can suspect that there will be yet higher bids coming if 
she accepts again, so she may have some incentive to say No to the second bid for 
strategic reasons. In fact, it is a common finding in the literature that the DBDC produces 
lower estimates than SBDC
15 and this can be explained by the arguments just given. 
 
However, although DBDC can be subject to some biases it provides more information 
than SBDC. This is has been called the “bias vs efficiency trade-off”
16. SBDC is less 
biased but it is less efficient. Also, it has been shown that the DBDC can help to avoid 
problems of bad choice of the first bid










DC has many advantages, as we have shown, but also has problems. The main 
disadvantage of the DC format is that each respondent provides less information about 
her preferences than other types of format. A CV survey typically has several versions, 
where each version uses a different set of bids for the WTP questions. The set of bids are 
distributed randomly across the sample. For this reason, it usually requires a larger 
sample and extensive piloting. Piloting is very important since the bids have to be 
distributed in such a way that they allow the researcher to get a good idea of the 
distribution of WTP preferences. It is very important to pick up the center and the 
extremes of the WTP distribution to be able to estimate central measures of tendency and 
also variability around these measures
18. 
 
Focus groups and pilot survey 
 
The survey was first piloted using administrative staff of the University as subjects. Once 
this first draft was modified three focus groups were held with a total of 17 participants. 
These focus groups were very useful to show that: 
 
a.  People were familiar with the potential fatal consequences of MI but did not have 
a basic understanding of the nature of this problem. In order to overcome this 
limitation the first part of the questionnaire explained to subjects some issues 
about the nature and consequences of a MI. 
b.  We had to insist that, if the MI was severe, the risk of death increased if the 
patient overcomes the acute phase. They had to understand that even if a 
medicine was effective, the risk of death for a person after a severe MI is higher 
than the risk of people with similar characteristics (same age and gender) that 
have not had an MI. We had to insist that an effective medicine reduces the risk 
of death but, even in this case, the risk of death after a severe MI remains higher 
than before the MI. In this way, the need for long-term medication was justified. 
c.  We had to use visual aids to illustrate the concept of risk. 
d.  People understood the risk better if explained as frequencies than as probabilities. 
 
After focus groups were held we conducted 50 interviews with the OE question. These 
interviews had two objectives. The first was to pilot the questionnaire again in a larger 
group. The second was to get information about the shape of the WTP distribution. We 
wanted to know the bids that where, approximately, in the 15%, 35%, 50%, 65% and 
85% percentiles of the distribution. In this way we have information about the center and 
about the dispersion. However, as there is evidence that people respond to binary 
questions in a different way from OE questions we conducted another pilot survey with 
120 subjects using the DC format. The bids we used were obtained from the information 
that we got from the OE survey. In fact, we checked that the percentage of affirmative 
responses in the DC survey was higher than predicted by the results of the OE 
questionnaire. We then introduced some changes in the bid design. After all this piloting 
we thought we had enough information about the bid distribution in order to conduct the 
final survey. The final bids were €30, €60, €90, €120 and €240 (payments per month) for 








these interviews were also very useful to check potential problems in the framing of the 
questions. 
 
The bids distributed in five different random sub-samples. The first and second bid of 
each group can be seen in Tables 1 and 2.  
 
 
TABLE 1 ABOUT HERE 
 




The final survey consisted of five parts. In the first part, we gave information to the 
subjects about what a MI was and their consequences. The key points that we 
emphasized were: a) after a severe MI the risk of death is higher than the risk of other 
people with the same characteristics, b) the effect of the medicine was to reduce the risk 
but not to return the patient to the same risk as before the MI. In the second part, subjects 
were asked about their WTP for the medicine in a DBDC ex-post frame. They were 
asked to assume that they had had an MI. We told them that the first year after the MI 
their risk of death was 16%, but, if they took the medicine, the risk of death would be 
reduced to 14% the first year after the MI. We told them that although the benefits 
(reduction in the risk of death) would also continue after the first year, it was the first 
year after the MI that most deaths would be prevented if they took the medicine. The 
question was then if they would be (or not) willing to pay a certain amount (the bid) 
monthly for five years. Although the duration of the treatment is an issue that has not 
been settled some experts told us that this was a reasonable assumption. In the third part, 
the ex-ante framing was explained. They were informed about their risk of having a MI 
next year and throughout their lives. They were told the probability of needing the 
medicine in the future. They were asked if they would vote in favor of a proposal to 
increase taxes by a certain amount next year in order to have access to this medicine if 
they had a MI. In the fourth part, we asked some attitudinal questions like if they thought 
that the medicine would have side effects or if they thought that the probability they 
would really need the medicine in the future was very low, low, high or very high. 
Finally, sociodemographic questions were asked. 
 
Consistency checks  
 
Estimates have to be consistent with some theoretical principles. Three kinds of 
consistency checks were performed. First, we observed if there was a positive correlation 
between WTP and income, since theory suggests that there has to be a positive 
correlation. Second, the percentage of people willing to pay a certain bid has to decrease 
as the bid increases. Third, WTP has to be larger when responses are elicited in an ex-
ante context. The reason is that in this case people not only pay according to the benefit 
that the medicine produces at the point of consumption, but also for the option value, that 








usual case when people pay to insure a good. The total amount that people pay in order 
to assure a good is higher than the value of the good itself. 
 
In order to compare ex-ante and ex-post WTP we will estimate WTP per patient 
according to each framework. The ex-post frame responds directly to this question, since 
this is the question (WTP per patient) that people are asked under this framing. The ex-
ante frame requires estimating the total amount of money that a group of taxpayers 
would pay and the number of people who would need the medicine in this group. 




For the analyses reported in this study, we use DBDC and SBDC formats to provide an 




The SBDC format only considered the first YES/NO responses. The probability of 
obtaining a ‘yes’ response in the SBDC model can be represented by, 
 
() ( ) BID WTP ob yes ob
y ≥ = = Pr Pr π      [ 1] 
and the probability of eliciting no response is ( )
y π − 1 .  
 
In this analysis, we use the logit model, so that 
y π takes the following form, 
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1
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where  () β α θ , ≡ , α andβ  are the estimated coefficients and BID is the certain amount 
asked to pay. Additional coefficients such as, for example, attitudes or sociodemographic 
information about the respondents may be included in the model. 
 
The most commonly used technique for estimating the logit model is the maximum 
likelihood (ML) estimation
19. The log-likelihood function following Hanemann et al
.17 is, 
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i d  is 1 if the ith response is “yes” to bid offer and 0 otherwise, while 
n
i d is 1 if 
the ith response is “no” and 0 otherwise. 
 
The mathematics of the DBDC format are a straightforward extension of the SBDC 
format
20. In DBDC format, each respondent is faced with two sequential bids. The level 
of the second bid is contingent upon the response to the first bid. Therefore, there are 








“yes” followed by a “no”; and (d) a “no” followed by a “yes”. The probabilities of these 
outcomes are  , , ,
yn nn yy π π π  and  ,
ny π  respectively
17. 
 
If  i d is a binary indicator variable for the “yes” or “no” responses to the two bid offers, 
then the log-likelihood function for the double-bounded model, parameterised by θ  is, 
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where  i BID  represents the starting bid value, 
d
i B  represents the follow-up lower bid 
value, and 
u
i B  represents the follow-up higher bid value. 
 
Under the assumption of a logistic distribution,  the mean and median coincide and may 
be obtained through  β α − , where α  is the constant and β  the bid coefficient, both 
estimated using the logit model. 
 
The confidence intervals around mean WTP were calculated using the Krinsky and 
Robb
21 (1986) procedure with 1000 repetitions.  
 
Data treatment 
The regression analysis and the rest of the data processing were undertaken using version 




The five groups were comparable in age, gender and income (Table 3). None of the 
differences between groups were statistically significant (p<0.05). In the case of income, 
the data were collected using 10 categories that we have reduced to three. Given the 
relevance of this variable and the influence that it has in WTP studies, we also converted 
it into a continuous variable by assuming that income was in the middle of each of the 10 
categories and we estimated the mean that can also be seen in table 3. 
 
TABLE 3 ABOUT HERE 
 
The result of YES responses to each group can be seen in tables 4 and 5. 
 
TABLE 4 ABOUT HERE 
 










As can be seen in both cases, there is a clear tendency of affirmative responses to 
decrease as the bid increases, as expected (Tables 4 and 5). In the ex-post part, the 
percentage of YES decreases more smoothly and the bids are more evenly spread than in 
the ex-ante case. Also, the three amounts in the middle pick up the center part of the 
distribution quite well. In the ex-ante scenario the second bid (€18) is too close the first 
and the third ones, adding little information about the shape of the WTP distribution 
function. There is also a sudden drop between bids three (€30) and four (€60), showing 
that it would have been better to have inserted another bid between these two amounts. 
However, we think that in both cases we picked up fairly well the shape of the WTP 
distribution since we have enough information on the central bids and the extremes.  
 
 
We estimated several models including all the sociodemographic and attitudinal 
variables collected in the survey. To save space, only the model with independent 
variables significant at the 0.05 level was kept. Sociodemographic variables such as 
gender or age were consistently insignificant and were removed from the final model. 
The final statistical model includes the bid, income and the perceived risk as independent 
variables. The later variable comes from the question that asked people about the 
possibility of needing the medicine in the future. The final model was estimated for the 
ex-ante and ex-post frameworks, according to the SBDC and DBDC models. All models 
were estimated by maximum likelihood, using the likelihood function in [3] for the 
SBDC formats, and that in [4] for the DBDC formats. 
 
The results of the logistic regression analysis are given in Table 6. All the variables 
considered in the analysis resulted to be determinants of WTP in the four models, except 
perceived risk in the SBDC model for the ex-ante framework. The perceived risk 
coefficient remains positive but is not statistically significant at the 95% confidence 
level. 
 
TABLE 6 ABOUT HERE 
 
The signs of the coefficients were as expected. The negative sign in the bid coefficient 
indicates that the probability of saying yes to a bid decreases when the value of the bid 
increases. On the other hand, respondents with higher incomes are more likely to accept 
the bid as denoted by the positive sign in the income coefficient. Finally, the perceived 
risk coefficient is positive, indicating that respondents with higher perception of needing 
Eplerenone in the future are more likely to agree to pay for medicine. In other words, 
since Eplerenone reduces mortality among patients with acute myocardial infarction, 
respondents with higher risk perception about suffering a heart attack are willing to pay 
more for the medicine. 
 
A goodness-of-fit for SBDC formats is the classification procedure, which counts the 
percentages of “hits and misses” obtained when the predicted outcomes are compared to 
the actual outcomes
22. Under this procedure, the SBDC formats, ex-ante and ex-post 
frameworks, yielded 76% and 78% accurate predictions, respectively (Table 6). To 








procedure proposed by Kanninen and Khawaja
20. This approach considers the proportion 
of fully, correctly classified cases (FCCC), counting the correctly classified cases with 
respect to the first question alone and then using only the observations that were 
correctly classified according to the first question to count the correctly classified cases 
for the second question (for a discussion on the merits and drawbacks of the sequential 
classification procedure, see
20). By using this procedure, the DBDC formats, ex-ante and 
ex-post frameworks, yielded an FCCC measure of 47% and 51%, respectively. The 
results of goodness-of-fit calculations are presented in Table 6. 
 
The estimates of the mean and their confidence intervals are presented in table 2 for all 
models. The confidence intervals around mean WTP were calculated using the Krinsky 
and Robb procedure with 1000 repetitions. The means WTP in the ex-ante framework 
are expected to be higher than in the ex-post case. In order to compare those mean WTP 
we assumed, for the ex-ante scenario, a cohort of 100 people with the average age of our 
sample (45 years), and that they all start paying €58 per year for the rest of their life 
(about 35 years). Note that this amount is the mean WTP obtained in both the SBDC and 
DBDC formats. The net present value of this is €1,082 (assuming a 4% discount rate). 
Using the incidence of MI in Spain and assuming that 27% of people with an MI that are 
discharged alive from hospital will use Eplerenone, we estimated at 3.6 the number of 
subjects who will use Eplerenone throughout their lives. Then, between the 100 people 
they would pay €108,200, and this amounts to €30,000 per patient (€108,200/3.6). Since 
in the certainty case we told people that treatment would last about 5 years, the €30,000 
per patient implies a monthly WTP of €500 for the treatment. This amount is larger than 
the €141 and €85 per patient and per month obtained from, respectively, the SBDC and 





This paper has shown how the Discrete Choice Contingent Valuation approach can be 
used to elicit preferences for a medicine that reduces the risk of death. We have obtained 
a different WTP under the SBDC than under the DBDC for the ex-post case. We have 
used two approaches (ex-ante and ex-post) that also have produced different results. 
Whereas the second discrepancy (ex-ante vs ex-post) can be attributed to theory, the 
same does not apply to the first discrepancy, SBDC vs DBDC. 
 
The use of DBDC has the main objective of narrowing the confidence interval. This is 
what happens when we compare the results of the SBDC with the DBDC in both the ex-
ante and ex-post case. However, in the ex-post case there is also another difference 
between SBDC and DBDC, namely, the two means are different and the SBDC provides 
a higher estimate than the DBDC method. This finding reproduces the tendency that has 
been found in the literature. This effect can be explained by the presence of a bias in the 
follow-up question (the second question), as we have explained above. There are two 
approaches to this problem. One is to try to model the bias and the other to use the 
estimates from the SBDC as the most valid since it is a less biased method
16.  We have 
tried the first approach according to a well know theory








shown). This should have led us to choose €141 as our best estimate under the ex-post 
framework. Although this is a legitimate approach, we think that there might be other 
kinds of bias in the contingent valuation method, like the hypothetical bias, that may 
increase our WTP estimates artificially. For this reason, we will consider €85 as our base 
case.  
 
The second discrepancy (ex-ante vs ex-post) does not come as a surprise since theory 
suggests this should be the case. The reason is that most people are willing to pay more 
than the expected value of a prospect for insurance coverage of the loss associated with 
that prospect. However, the theory does not say anything about the magnitude of this 
difference. In O’Brien et al
9 the willingness to pay per episode of Febrile Neutropenia 
Avoided was $33,000 with the user-based (ex-post) approach and €1,200,000 with the 
insurance-based (ex-ante) approach. That is, a WTP more than 30 times larger in the 
insurance-based approach. In our approach, WTP per fatality avoided is about 6 times 
larger with the insurance based approach. Although this difference is smaller than in 
O’Brien et al, it is large enough to merit some degree of concern. One possibility is to 
explain the difference between these two values by the degree of risk aversion. The 
higher the risk aversion, the more people are willing to pay to buy insurance to insure an 
object of a constant subjective value. The other possibility is that people have found 
problems in valuing the two risks that are relevant for this question, that is, the risk of 
having a MI and the risk reduction if they take Eplerenone leading to a WTP that it is too 
high. Unfortunately, we cannot infer from the survey which of the above explanations 
underlies that difference. 
 
It is quite clear that both framings provide different estimates and the question is which 
of the two should be used in social decision-making. Should the government spend €85 
or €500 per month on Eplerenone? One way of solving the problem is to apply theory. 
According to it, the correct framework is the one that uses taxes
8. However, from a 
practical point of view, this framework is much more cognitively demanding since it 
involves the computation of two probabilities. If people have problems with working 
with probabilities (as it has been shown they have), the tax frame can produce estimates 
that are less reliable. Johannesson
11 has shown that, under certain conditions, willingness 
to pay ex-post can be considered as a conservative estimate of ex-ante WTP. That is, if 
we think that ex-ante WTP is the correct framework but we consider that it is too 
cognitively demanding we can use ex-post WTP as a lower bound for ex-ante WTP. The 
response to the above question is therefore that there are no clear arguments to choose 
€85 or €500 as the correct amount, but we can say that €85 is theoretically correct as well 
as a conservative estimate. The probability that the government will make an inefficient 
decision if it spends €85 per month on Eplerenone is quite low. Also, some authors have 
argued that WTP estimates can be upward-biased due to the hypothetical nature of the 
question
23, and this is another argument to use €85 instead of €500 as a conservative 
estimate of WTP. 
 
However, while accepting that €85 per month is a conservative estimate, we also want to 
mention that there are reasons to think that this amount is too low and that an amount 








would imply a value of a statistical life that, according to many standards, would be too 
low. To see this, assume that our subjects pay €85 per month for 5 years. This amounts to 
about €4500 in net present value. If 100 of them pay €4500 and fatalities are reduced by 
2%, there would be 2 fewer fatalities in the group of 100. As they would have spent 
€450,000, this would imply a value of a statistical life of about €225,000. The figures 
that are used in the literature are clearly higher. For example, in Europe, a recent study
24 
funded by the European Commission (EC) has estimated at one million euros the value 
of a fatality prevented, so our conservative estimate of €85 per month may indeed be too 
conservative. 
 
There is a final question we would like to clarify and it deals with the relation between 
cost-effectiveness thresholds and our WTP estimates. There is one cost-effectiveness 
study of Eplerenone
25. It found that the cost per life year gained using Eplerenone is of 
about €13,000 per life year gained. In order to judge if this is too high or too low there 
has to be some external benchmark to which this number must be compared. The 
advantage of WTP (and CBA) with respect to CEA is that we do not need an external 
benchmark since the figure we get from the study is the benchmark. 
 
The paper has at least two limitations that can be the subject of further research. One is 
the study of scope effects
26. By “scope effects” we mean the sensitivity of WTP to the 
size of the health gain. In order to study scope effects we would have needed at least 
another similar group where we would have used a different risk reduction. If we had 
used a smaller risk reduction we would expect to get a lower WTP. The study of scope 
effects is then a very interesting issue for further research. The second is the role of the 
payment and benefit duration in the framing of the WTP question. In our framing we 
only mentioned the short term effects of Eplerenone since the clinical evidence is 
restricted to the duration of the trial. However, since it is expected that the benefit will 
last further it would be interesting also to provide information on the benefits of 
Eplerenone in subsequent years (and not only of the first year) and see if this would 
affect WTP. However, at the time of conducting this survey we did not have very clear 
evidence of this benefit and we then chose (again) a conservative option. Finally, 
although we do not consider this, strictly speaking, a limitation, we think that it would 
also be an interesting research topic to elicit WTP from patients. However, this may run 
into ethical problems, since this would require informing people about their risk of death 
and about their life expectancy. The first is much higher than the risk of the general 
population and the second is much lower that the life expectancy of the general 
population. To provide this information to patients without causing them unnecessary 
suffering is a real challenge. 
 
In conclusion, this study has shown that it is feasible to use Contingent Valuation in 
order to measure the benefits of a medicine that reduces the risk of death after MI. Our 
results show that this benefit is in a range that moves between €85 and €500. We 
therefore consider that €85 per month is a conservative estimate of the benefits produced 






























Table 1. Bid structure (€) for the ex-post case. 
Group  Initial Bid  Upper bid B
u   Lower Bid B
d 
I 30  60  15 
II 60  90  30 
III 90  120  60 
IV 120  240 90 
V 240  300  120 
 
Table 2. Bid structure (€) for the ex-ante case. 
Group  B  B
u  B
d 
I 6  18  1 
II 18  30 6 
III 30 60 18 
IV 60 90 30 
V 90  120  60 
 
Table 3. Socio-demographic characteristics (n=70 per group) 
Income (%)  Group  Age (mean)  Gender (% women)
Low Middle High Mean (monthly €)
1 45.5  48.6  35.7 55.7  8.6  1077 
2 44.8  50.0  38.6 45.7  15.7  1097 
3 44.7  50.0  32.9 52.9  14.3  1140 
4 46.3  52.9  40.0 50.0  10.0  1069 
5 45.3  51.4  35.7 58.6  5.7  1056 
 
Table 4. Percentage of affirmative responses to SBDC and DBDC (ex-post case) 
Group  B  % Yes to B  B
u %  Yes  to  B
u  B
d %  Yes  to  B
d 
I  30 89% 60  66%  15  10% 
II  60 67% 90  34%  30  17% 
III  90 43%  120  14%  60  29% 
IV  120  26%  240 7% 90 26% 
V  240 10% 300  4%  120  14% 
 
 
Table 5. Percentage of affirmative responses to SBDC and DBDC (ex-ante case) 
Group  B  % Yes to B  B
u  % Yes to B
u  B
d %  Yes  to  B
d 
I  6 91%  18  70%  1  6% 
II  18 80%  30  43%  6  11% 
III  30 73%  60  40%  18  17% 
IV  60 40%  90  24%  30  39% 









Table 6. Regressions with better fit. 
 Ex-post  Ex-ante 








Variable SBDC  DBDC  SBDC  DBDC 
































Observations 350 350  350  350 
Mean WTP (€)
+ 141.2  85.061  58.012 58.04 
Confidence 
interval 95%
#  [88.3, 199.4] [50.1,121.4]  [24.9,94.9]  [36.2,80.5] 
% of hits  78%  78%  76%  76% 
FCCC   51%    47% 
* 1% level  # 5% level 
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